In this trial, done at 43 centres in France, the authors randomly assigned patients receiving invasive mechanical ventilation for up to 72 h with COVID-19 and associated moderate-to-severe ARDS to receive either IVIG or placebo.

Adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.

In this study the authors did a multicentric, open-label, Bayesian randomised, adaptive, phase 2/3 clinical trial, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis.

In this article the authors aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines.

In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19.

In this trial, nonhospitalized patients with symptomatic COVID-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression received a single infusion of sotrovimab at a dose of 500 mg or placebo.

The EAN Education Committee is happy to announce and introduce the recipients of the 2022 Student Teaser Fellowship. Congratulations to the winners!

In this study the authors used data on confirmed infection and severe disease collected from an Israeli national database for the period of July 11 to 31, 2021, for all Israeli residents who had been fully vaccinated before June 2021.

Safe, effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed in children younger than 12 years of age. In this article the authors present results for 5-to-11-year-old children.

The objective of this double-blind randomised controlled trial was to compare propranolol and topiramate in terms of tolerability and efficacy in preventing chronic migraine over 24 weeks.

This randomized, double-blind, placebo-controlled phase 2 clinical trial investigated the potential therapeutic value of losartan, an angiotensin II receptor antagonist, in reducing whole brain volume atrophy in patients with mild-to moderate Alzheimer’s disease.

Registration is now open for the OneNeurology European Summit, taking place virtually on Friday, 17 December.

With so few chances for EAN staff and members to meet in person, we decided to introduce the team behind the scenes. This time it's Florian, our Congress Manager, and Helene, from the Education Department.

The EAN Spring School is available to 120 clinical neurologists in training who have not yet completed their residency or clinical speciality training.

The EAN Education Committee has received numerous applications for the 2022 Research Fellowship and we are happy to announce and introduce the recipients below.